期刊文献+

乳腺癌患者血清中MMP-2、MMP-9的表达及与乳腺钼靶X线征象的关系

Expressions of serum MMP-2 and MMP-9 in the breast cancer and their relationships with molybdenum target X-Ray scanning
下载PDF
导出
摘要 目的探讨乳腺癌患者血清中基质金属蛋白酶(MMP)-2和MMP-9的表达及与乳腺钼靶X线征象的关系。方法采用双抗体夹心ELISA法检测85例乳腺癌患者MMP-2、MMP-9的表达,并对所有患者进行乳腺钼靶X线扫描,然后分析两者表达与乳腺钼靶X线主要征象的关系。结果乳腺癌患者血清中MMP-2、MMP-9的表达水平分别为(113.41±10.22)μg/L、(174.27±10.97)μg/L。乳腺癌患者血清中MMP-2、MMP-9的表达水平与毛刺征、钙化征、淋巴结转移征关系密切(P<0.05)。结论 MMP-2、MMP-9的高表达是乳腺癌预后较差的预后因子,且两者均与毛刺征、钙化征、淋巴结转移征阳性关系密切,可能是其阳性征象的组织病理学基础。 Objective To investigate the expressions of serum matrix metalloproteinases (MMP) -2 and MMP-9 in the breast cancer, and to analyze their relationships with molybdenum target X-ray scanning. Methods A double antibody sandwich ELISA assay was used to detected the serum MMP-2 and MMP-9 in the 85 patients with breast cancer, and all the patients received the molybdenum target X-ray scanning, and the relationship with molybdenum target X-ray imaging were analyzed. Results The expression levels of serum MMP-2 and MMP-9 in the breast cancer were (113.41&#177;10.22) and (174.27&#177;10.97)μg/L, respectively. The expressions of serum MMP-2 and MMP-9 were related with burr syndrome, calcification and lymph node metastasis (P&lt;0.05). Conclusion High expressions of MMP-2 and MMP-9 are the signs of poor grognosis of breast cancer, and their high expressions are positively related with positive burr syndrome, positive calcification and positive lymph node metastasis, and they can be pathology basis of the positive signs.
作者 孙淑军
出处 《中国现代药物应用》 2014年第5期30-31,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献5

二级参考文献77

  • 1王怡,王涌,张希敏,秦茜淼,王意达,徐智章.组织弹性成像鉴别乳腺良恶性肿块的价值评估[J].中国医学影像技术,2005,21(11):1704-1706. 被引量:103
  • 2罗葆明,欧冰,智慧,曾婕,杨海云.改良超声弹性成像评分标准在乳腺肿块鉴别诊断中的价值[J].现代临床医学生物工程学杂志,2006,12(5):396-398. 被引量:370
  • 3Quesada V, Ordonez GR, Sanchez LM, et al. The Degradome da- tabase : mammalian proteases and diseases of proteolysis [ J ]. Nuc Acids Res,2009,37 ( Database issue) : D239 - 243.
  • 4Hiraoka N, Allen E, Apel lJ, et aL Matrix met alloproteinases regulate neovascularization by acting as pericellular fibrinolysins [ J ]. Cell, 1998,95 : 365 - 377.
  • 5Tallant C, Marrero A, Gomis - Ruth FX. Matrix met alloproteinas- es: fold and function of their catalytic domains [ J ]. Biochim Bio- phys Acta,2009,04:20 - 28.
  • 6Nagase H, Visse R, Murphy G. Structure and function of matrix met allopreteinases and TIMPs[ J]. Cardiovasc Res ,2006,69 ( 3 ) : 562 - 573.
  • 7Overall CM, Kleifeld O. Towards third generation matrix met allo- proteinase inhibitors for cancer therapy[ J]. Br J Cancer,2006,94 (7) :941 -946.
  • 8Visse R, Nagase H. Matrix met alloproteinases and tissue inhibi- tots of met alloproteinases : structure, function, and biochemistry [ J ]. Cire Res,2003,92 (8) :827 - 839.
  • 9Rosenblum G, Meroueh S, Toth M, et al. Molecular structures and dynamics of the stepwise activation mechanism of a matrix met alloproteinase zymogen: challenging the cysteine switch dogma [J]. J Am Chem Soc,2007,129(44) :13566 -13574.
  • 10Sela - Passwell N, Rosenblum G, Shoham T, et al. Structural and functional bases for allosteric control of MMP activities : Can it pave the path for selective inhibition[ J] ? Biochim Biophys Acta, 2009,04:29 - 38.

共引文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部